MapLight Therapeutics, Inc. filed a Current Report on Form 8-K on November 16, 2026, announcing its financial results for the third quarter ended September 30, 2026, and an updated corporate presentation furnished under Regulation FD.

Key Highlights

  • Reporting period: Financial results cover the third quarter ended September 30, 2026.
  • Press release furnished: A press release dated November 16, 2026 was attached as Exhibit 99.1.
  • Corporate presentation updated: An updated investor presentation dated November 16, 2026 was furnished as Exhibit 99.2 and made available on the company's website.
  • Emerging growth company: MapLight Therapeutics is designated as an emerging growth company under applicable SEC rules, according to the filing.
  • Signed by CEO: The report was signed by Christopher A. Kroeger, M.D., Chief Executive Officer.

MapLight Therapeutics Furnishes Q3 2026 Financials and Updated Presentation

MapLight Therapeutics, Inc. (NASDAQ:MPLT), headquartered at 800 Chesapeake Drive, Redwood City, California 94063, filed a Current Report on November 16, 2026, covering two items. Under Item 2.02, the company disclosed that it issued a press release on November 16, 2026 announcing its financial results for the third quarter ended September 30, 2026. That press release was furnished as Exhibit 99.1 to the report.

Under Item 7.01, the company disclosed that it updated its corporate presentation on November 16, 2026, intended for use in meetings with investors, analysts, and others. According to the filing, the presentation was made available on the company's website and was also furnished as Exhibit 99.2. The filing notes that the information provided under Items 2.02 and 7.01, along with the accompanying exhibits, is furnished and "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934," nor incorporated by reference into any of the company's other filings unless specifically referenced.

The company identified itself as an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, and indicated it has not elected to use the extended transition period for complying with new or revised financial accounting standards. The report was signed by Christopher A. Kroeger, M.D., in his capacity as Chief Executive Officer.

What Was Disclosed

MapLight Therapeutics filed an 8-K on November 16, 2026 to furnish its Q3 2026 earnings press release and an updated corporate investor presentation, both dated November 16, 2026, as exhibits to the report.